Igenica Raises $33M in Series C Funding
Igenica, Inc., a Burlingame, CA-based biopharmaceutical company developing antibody-based cancer medicines, has raised $33m in Series C round of funding.
The round was led by new investor Third Rock Ventures, with participation from existing investors The Column Group, Orbimed Advisors and 5AM Ventures.
The company intends to use the capital to advance its monoclonal antibody pipeline toward clinical trials against a broad range of drug targets for the treatment of cancer.
Led by David Goeddel, Ph.D., Executive Chairman, Igenica has integrated technology platforms to develop treatments for multiple oncology indications, with sTAg, a new approach to discovering and prioritizing novel tumor antigens, and iTAb, a functional in vivo antibody screening approach.